Finerenone - Generic Drug Details

What are the generic drug sources for finerenone and what is the scope of patent protection?

Finerenone is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Finerenone has ninety-eight patent family members in fifty countries.

One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for finerenone

International Patents:	98
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	55
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for finerenone
What excipients (inactive ingredients) are in finerenone?	finerenone excipients list
DailyMed Link:	finerenone at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for finerenone

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for finerenone

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mansoura University	PHASE4
College of Physicians and Surgeons Pakistan	NA
Sarfez Pharmaceuticals, Inc.	PHASE3

See all finerenone clinical trials

Generic filers with tentative approvals for FINERENONE

Applicant	Application No.	Strength	Dosage Form
		20MG	TABLET; FILM COATED

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for finerenone

Drug Class	Nonsteroidal Mineralocorticoid-Receptor Antagonist
Mechanism of Action	Mineralocorticoid Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for finerenone

C03DA	Aldosterone antagonists
C03D	ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS
C03	DIURETICS
C	Cardiovascular system

Paragraph IV (Patent) Challenges for FINERENONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KERENDIA	Tablets	finerenone	40 mg	215341	1	2026-02-02
KERENDIA	Tablets	finerenone	10 mg and 20 mg	215341	9	2025-07-09

US Patents and Regulatory Information for finerenone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-002	Jul 9, 2021		RX	Yes	No
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-002	Jul 9, 2021		RX	Yes	No				Y
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-001	Jul 9, 2021		RX	Yes	No				Y
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-001	Jul 9, 2021		RX	Yes	No
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-003	Jul 11, 2025		RX	Yes	Yes
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-002	Jul 9, 2021		RX	Yes	No
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-003	Jul 11, 2025		RX	Yes	Yes			Y	Y

EU/EMA Drug Approvals for finerenone

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bayer AG	Kerendia	finerenone	EMEA/H/C/005200Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.	Authorised	no	no	no	2022-02-16

International Patents for finerenone

Country	Patent Number	Title	Estimated Expiration
Argentina	065463
Australia	2008221071
Brazil	122020008544
Brazil	PI0808098
Canada	2679232
Chile	2008000502
China	101641352

Supplementary Protection Certificates for finerenone

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2132206	301192	Netherlands		PRODUCT NAME: FINERENON EN ZIJN ZOUTEN, SOLVATEN EN SOLVATEN VAN DE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/21/1616 20220217
2132206	CA 2022 00025	Denmark		PRODUCT NAME: FINERENONE OG DETS SALTE, SOLVATER OG SOLVATER AF SALTENE DERAF; REG. NO/DATE: EU/1/21/1616 20220217
2132206	LUC00260	Luxembourg		PRODUCT NAME: FINERENONE, SES SELS ET SOLVATES AINSI QUE LES SOLVATES DES SELS DE FINERENONE; AUTHORISATION NUMBER AND DATE: EU/1/21/1616 20220217
2132206	PA2022512	Lithuania		PRODUCT NAME: FINERENONAS; REGISTRATION NO/DATE: EU/1/21/1616 20220216
2132206	CR 2022 00025	Denmark		PRODUCT NAME: FINERENONE OG DETS SALTE, SOLVATER OG SOLVATER AF SALTENE DERAF; REG. NO/DATE: EU/1/21/1616 20220217
2132206	2022C/538	Belgium		PRODUCT NAME: FINERENON EN ZIJN ZOUTEN, SOLVATEN EN SOLVATEN VAN DE ZOUTEN DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1616 20220217
2132206	22C1017	France		PRODUCT NAME: FINERENONE ET SES SELS, SOLVATES ET SOLVATES DES SELS.; REGISTRATION NO/DATE: EU/1/21/1616 20220217

Last updated: July 16, 2026

Finerenone market dynamics and financial trajectory: growth drivers, pricing pressure, exclusivity timeline, and earnings exposure

Finerenone is the non-steroidal mineralocorticoid receptor antagonist (nsMRA) marketed by Bayer as Kerendia. In 2023 it was a meaningful contributor to Bayer’s royalty base and commercial platform for renal and cardiovascular disease, and in 2024–2025 it expanded global penetration through label breadth and guideline uptake. The next step-change in revenue risk sits in (1) exclusivity and generic/biosimilar entry timing (small-molecule generics), (2) payer and pricing resets in the US as formulary access matures, and (3) competitive adsorption as SGLT2 inhibitors and GLP-1 receptor agonists dominate first-line sequencing in type 2 diabetes kidney disease.

Quick answer (business-relevant)

• Primary revenue engine: Kerendia (finerenone) chronic kidney disease (CKD) in adults with type 2 diabetes at risk of CKD progression and cardiovascular events, in combination with optimized renin-angiotensin system blockade (ACE inhibitor or ARB).
• Near-term market dynamic: US commercial growth is capped by payer utilization management, co-pay dynamics, and therapy positioning vs SGLT2 inhibitor-centered regimens.
• IP risk: Finerenone is a small molecule; generic entry is the main threat. Patent cliffs and any Orange Book listings define the timing, scope, and formulation-specific barriers.
• Financial trajectory: Bayer’s reported segment reporting shows finerenone is part of Bayer’s Pharmaceuticals ex-R&D and commercialization income profile, with contribution influenced by royalty/partner economics in some geographies and by net price under reimbursement.

---

How is finerenone (Kerendia) priced and reimbursed across major markets, and what drives net sales?

Net sales are determined by launch maturity, formulary access, and the interaction with SGLT2 inhibitor adoption. For small molecules like finerenone, gross-to-net is typically shaped by (1) rebates and discounts (including managed care outcomes), (2) patient assistance and specialty pharmacy purchasing, and (3) Medicare Part D placement in the US where specialty-tier dynamics influence adherence.

What reimbursement and sequencing dynamics matter most?

• Therapy sequencing: In type 2 diabetes with CKD, clinicians often start with an SGLT2 inhibitor plus ACE inhibitor/ARB, then add an nsMRA for residual risk reduction. If guideline recommendations move finerenone earlier in treatment, utilization can expand faster than expected.
• Payer management: Restrictive prior authorization, step therapy policies, and diagnosis coding requirements can slow uptake even when clinical outcomes support use.
• Regional pricing dispersion: Europe and Japan generally show slower early price compression but still face periodic national tender and HTA-driven resets.

Commercial KPIs that predict future financial trajectory

• Share of eligible CKD-with-diabetes patients on finerenone after SGLT2 uptake.
• Persistency and refill rates in specialty channels.
• Net price per claim versus list price, by payer class.
• Uptake rate by stage (CKD severity) and baseline albuminuria, tied to label inclusion and outcomes evidence.

---

What clinical outcomes are supporting finerenone uptake, and how do they map to prescribing behavior?

Finerenone’s commercial adoption is anchored in cardiovascular and kidney outcomes evidence that fits payer-friendly endpoints: reduction in kidney disease progression and cardiovascular events in CKD patients with type 2 diabetes on optimized RAAS blockade.

Outcomes evidence that underpins payer and clinician uptake

• Kidney outcomes: Reduction in progression of CKD endpoints in a population aligned to label use.
• Cardiovascular outcomes: Reduction in cardiovascular events, supporting broadening beyond nephrology specialists.

Behavior shifts tied to label interpretation

• Cross-specialty adoption: The dual focus on kidney and cardiovascular outcomes pulls cardiology and endocrinology into prescribing pathways that were once nephrology-only.
• Earlier intervention as evidence is assimilated: As real-world evidence accumulates, prescribers tend to treat residual risk earlier, expanding eligible populations.

---

When does finerenone lose exclusivity in the US and EU, and what does that mean for generic entry risk?

For a small molecule like finerenone, generic entry timing is driven by patent term and any Orange Book-protected exclusivities (where applicable), plus litigation/settlement events.

What matters for exclusivity and generic launch

• Patent estate coverage: Composition of matter patents, method-of-use patents, and formulation/manufacturing patents can each block different generic strategies.
• Orange Book listings: FDA-registered patents associated with approved finerenone products determine what has to be overcome.
• Paragraph IV strategy: If a generic files under Paragraph IV (Hatch-Waxman), the first applicant can trigger a 30-month stay if litigation is timely, but only to the extent patents are challenged successfully or at least litigated.

Practical financial impact model

• Pre-cliff growth: Continued net sales growth depends on payer access plus label breadth.
• Cliff effect: Generic entry, even if delayed, can create a step-change in volumes and net price. For specialty oral drugs, price erosion can begin with market entry and settle over subsequent quarters.
• Formulation differentiation: If only method-of-use patents expire earlier than composition-of-matter coverage, generics can be delayed even when some clinical uses are no longer protected.

(This section cannot be populated with specific expiration dates, Orange Book patent numbers, or litigation triggers without a complete and current patent-by-patent Orange Book and court docket extraction.)

---

What patents protect finerenone (Kerendia), and how strong is the patent estate by category (composition, formulation, method of use)?

A robust estate for finerenone typically includes:

• Composition of matter: Protecting the active pharmaceutical ingredient (API).
• Salt form and crystalline form: If applicable to the marketed substance.
• Method of use: Covering patient subsets, dosing regimens, and combination approaches (for example, with RAAS inhibitors).
• Formulation/manufacturing: Sustained release, particle size, tablet/capsule-specific specs, and process improvements.

Estate strength indicators used by litigators and investors

• Number of active US Orange Book-listed patents per product.
• How many are composition-of-matter vs dependent claims (method and formulation).
• Whether key patents are single-factor determinants (one patent blocks all).
• Prosecution history and claim scope breadth.
• Prior art density around nsMRA chemistry and crystalline/formulation variants.

(Patent numbers, assignees, and expiration dates are not listed here because the request requires a complete and accurate estate mapping that depends on the current Orange Book and USPTO and court record inputs.)

---

Which companies are most likely to challenge finerenone with Paragraph IV ANDA filings, and what generic entry risks exist?

Generic entry risk is driven by:

• Presence of ANDA filers with credible patent challenges.
• Court outcomes that narrow remaining barriers.
• Timing of any settlement agreements that align with FDA approval and launch sequencing.

What to watch in Paragraph IV scenarios

• First-filer advantage: First ANDA filer often secures exclusivity on entry if patent challenges align with injunction/authorization outcomes.
• Design-around: If patent scope focuses on combination use or method-of-use claims, challengers may seek non-infringing labeling.
• Risk of delayed launch: If key composition-of-matter patents remain in force, generic approvals can be blocked regardless of method-of-use carve-outs.

(Company list and specific filings are omitted because a correct answer requires an up-to-date Paragraph IV and ANDA docket/patent link to finerenone.)

---

How does finerenone compare with other CKD-in-type-2-diabetes drugs (SGLT2 inhibitors, GLP-1 RAs, other MRAs), and what does that imply for future revenue?

Finerenone competes and complements rather than replaces. Market share is influenced by patient eligibility, tolerability, and payer preference for outcome-proven regimens.

Competitive positioning

• SGLT2 inhibitors: Usually first-line for cardiorenal risk in type 2 diabetes CKD; finerenone is commonly added for residual risk.
• GLP-1 receptor agonists: Focus on glycemic control and cardiovascular risk; their role in CKD progression can drive overlapping use-cases.
• Other MRAs: Steroidal MRAs have hyperkalemia constraints; finerenone’s differential benefit-risk supports broader adoption with appropriate monitoring.

Revenue implication

• Finerenone’s upside is less about substitution and more about incremental adoption within RAAS-blockade patients and guideline-based residual risk.
• Downside is mainly pricing/reimbursement pressure and if prescribers pivot to other add-on mechanisms with broader coverage or lower monitoring burden.

---

What financial trajectory indicators show whether finerenone is accelerating or facing saturation?

Investors typically look at:

• Global net sales growth rate by region (US vs EU vs ROW).
• Prescription volume and patient counts from specialty pharmacy reporting where available.
• Net price trends through payer contracts and formulary tiers.
• Share of CKD-in-diabetes eligible population on finerenone.

Where saturation typically shows up

• Once a therapy reaches broad formulary access, growth becomes dependent on new patient identification and increased persistence.
• If real-world safety management reduces discontinuations but raises monitoring overhead, net volume can still lag despite clinical uptake.

---

How do partnerships, licensing, and geographic commercialization arrangements affect finerenone earnings?

Commercial structure matters:

• In some territories, Bayer’s economics can depend on partner distribution, co-promotion, or licensing terms.
• Royalties can stabilize earnings even when unit volumes fluctuate, but can introduce variability from partner performance.

Earnings sensitivity channels

• Exchange rates and local net price.
• Partner sales reporting and royalty basis (ex-manufacturer vs wholesale).
• Commercial milestones tied to launches and target access.

(This section is limited to directional mechanics. Specific partner arrangements, royalty rates, and territory splits require extraction from Bayer disclosures tied to the finerenone product structure.)

---

What litigation, settlements, or regulatory events could materially change finerenone’s market access?

Finerenone’s market access is exposed to:

• Patent litigation outcomes affecting generic timing.
• Regulatory labeling changes that shift eligible populations.
• Safety communications tied to hyperkalemia risk monitoring.

Key litigation pathways for small molecules

• Hatch-Waxman patent disputes.
• If settlement occurs, it can define an agreed launch date, at times combined with agreed labeling carve-outs.

(No case list or settlement dates are provided because a complete, accurate mapping requires up-to-date court and FDA Orange Book extraction.)

---

What is the FDA regulatory status of finerenone (Kerendia), and how might new labeling expand or constrain the market?

Finerenone is FDA-approved for adults with CKD associated with type 2 diabetes to reduce risk of:

• CKD progression,
• cardiovascular events, in the context of optimized RAAS inhibition.

Regulatory dynamics that can shift revenue

• Label expansions increase addressable population.
• Safety labeling or monitoring updates can increase physician adoption friction but can also reduce discontinuations if they improve management.
• Post-marketing studies can refine prescriber confidence and payer willingness.

(A detailed FDA review timeline, supplement dates, and current labeling versioning is omitted because it requires a product-level extraction.)

---

What formulation and dosing aspects can be protected, and how do they shape generic design?

Generic design for small molecule oral tablets can include:

• Different salt form (if relevant),
• Different particle size,
• Different excipients,
• Different dissolution characteristics,
• Bioequivalence strategy.

How formulation patents typically block generics

• If formulation patents are still active, generic challengers may need to license.
• If only method-of-use patents are active, challengers can still launch with non-infringing labeling, accelerating erosion risk.

(Specific finerenone formulation patents are not enumerated without a current patent-to-product mapping.)

---

How does finerenone’s market forecast change under different generic launch scenarios?

A practical scenario framework for earnings exposure:

• Base case: slow price erosion with delayed generic entry.
• Downside case: earlier generic entry due to successful Paragraph IV challenges or settlements.
• Upside case: continued patent resilience plus payer-driven expansion beyond initial eligible populations.

What typically determines how fast price falls

• Number of entrants at launch.
• Whether branded manufacturers defend with injunctions.
• Payer switching behavior and channel contract terms.

(Quantified scenario modeling with specific entry dates cannot be produced without an accurate exclusivity expiration timeline.)

---

Key Takeaways

• Finerenone’s financial trajectory is driven by incremental adoption in CKD with type 2 diabetes on RAAS blockade, reinforced by kidney and cardiovascular outcome data.
• Near-term growth is constrained by payer access, sequencing against SGLT2 inhibitors, and net price pressure as formularies mature.
• Generic risk is the dominant long-run market threat for a small molecule, governed by the Orange Book patent estate and any Paragraph IV litigation and settlement timing.
• Revenue durability depends on whether Bayer’s remaining patent coverage blocks composition/formulation strategies or only method-of-use labeling.

---

FAQs

1. Does finerenone compete head-to-head with SGLT2 inhibitors or is it mainly an add-on?
2. What reimbursement barriers most often slow finerenone uptake in the US?
3. How do method-of-use versus composition-of-matter patents affect generic launch timelines for finerenone?
4. What safety monitoring requirements (hyperkalemia) influence real-world persistence for Kerendia?
5. How quickly does price typically erode after generic entry for specialty oral cardiovascular-nephrology drugs like finerenone?

---

References

1. Bayer. Kerendia (finerenone) prescribing information.
2. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Kerendia/finerenone entries).
3. FDA. Drug approvals and labeling database (Kerendia/finerenone).